Novo Nordisk A/S (NVO) 54.72 $NVO
Study Finds Victoza® Significantly Reduced the Risk of Heart Attack and Stroke in People with Type 2 Diabetes
CNW Group - Mon Jun 13, 7:52PM CDT
Diabetes community welcomes news that Victoza(® )reduces the risk of cardiovascular deaths by 22 per cent
NVO: 54.72 (-0.64)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 4:23PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $54.20 to a high of $55.45. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $55.12 on volume of 608,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 54.72 (-0.64)
Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1 diabetes and a comparable HbA(1c) reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
CNW Group - Mon Jun 13, 11:40AM CDT
Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes
NVO: 54.72 (-0.64)
Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
PR Newswire Europe - Mon Jun 06, 6:36AM CDT
BAGSVARD, Denmark, June 6, 2016 /PRNewswire/ --
NVO: 54.72 (-0.64)
Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) - Research and Markets
BusinessWire - Fri Jun 03, 8:34AM CDT
Research and Markets has announced the addition of the "Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
NVO: 54.72 (-0.64)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), NVO: 54.72 (-0.64), SNY: 39.00 (-0.41)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 60.03 (+0.02), NVO: 54.72 (-0.64), BMY: 72.22 (-0.43), SNY: 39.00 (-0.41)
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), NVO: 54.72 (-0.64), SNY: 39.00 (-0.41)
IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
PR Newswire - Tue May 24, 6:39PM CDT
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of Tresiba® (insulin degludec injection 100 Units/mL) and Victoza® (liraglutide) injection for the treatment of adults with type 2 diabetes.
NVO: 54.72 (-0.64)
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Globe Newswire - Tue May 24, 4:24PM CDT
Bagsvaerd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)) for the treatment of adults with type 2 diabetes.
NVO: 54.72 (-0.64)
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 54.72 (-0.64), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), SNY: 39.00 (-0.41)
US and Europe Insulin Market 2016-2020 - Key Vendors are Sanofi, Novo Nordisk & Eli Lilly
GlobeNewswire - Tue May 24, 5:20AM CDT
Research and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering.
NVO: 54.72 (-0.64), LLY: 73.86 (-0.09)
AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 54.72 (-0.64), SCMP: 10.83 (-0.87), SCLN: 14.36 (+0.73), BIOD: 0.33 (-0.01)
Global Non-alcoholic Steatohepatitis Market 2016-2020 - Key Vendors are GSK, Novo Nordisk & Vivus - Research and Markets
BusinessWire - Fri May 20, 11:06AM CDT
Research and Markets has announced the addition of the "Global Non-alcoholic Steatohepatitis Market 2016-2020" report to their offering.
NVO: 54.72 (-0.64)
FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide
Globe Newswire - Fri May 20, 7:36AM CDT
Bagsvaerd, Denmark, 20 May 2016 - Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the 24 May 2016 Advisory Committee meeting to discuss the New Drug Application (NDA) for IDegLira, the fixed combination product of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)).
NVO: 54.72 (-0.64)
Look for Shares of Novo Nordisk to Potentially Rebound after Yesterday's 1.38% Sell Off
Comtex SmarTrend(R) - Thu May 19, 3:26PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $53.45 to a high of $54.12. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $54.01 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 54.72 (-0.64)
Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of haemophilia B
Globe Newswire - Mon May 16, 9:36AM CDT
The paradigm clinical trial programme for nonacog beta pegol enrolled children and adults with severe or moderately severe haemophilia B. A total of 115 previously treated patients with a total of more than 10,625 exposure days for up to 3.3 years of treatment with nonacog beta pegol.
NVO: 54.72 (-0.64)
Novo Nordisk, Chip Ganassi Racing Teams and Charlie Kimball Honor the Diabetes Community With the No. 42 Tresiba® (insulin degludec injection 200 Units/mL) Chevrolet at the 100th Running of the Indianapolis 500
PR Newswire - Mon May 16, 8:30AM CDT
Chip Ganassi Racing Teams (CGRT) and longtime partner Novo Nordisk, a world leader in diabetes care, along with their Verizon IndyCar Series driver Charlie Kimball, will join together to honor the diabetes community at the 100th running of the Indianapolis 500.
NVO: 54.72 (-0.64)
Retail, Food Service, Child Care and Health Care Leaders to Sponsor Partnership for a Healthier America's Building a Healthier Future Summit
PR Newswire - Mon May 09, 5:13PM CDT
The Partnership for a Healthier America (PHA), which works with the private sector and PHA Honorary Chair First Lady Michelle Obama to make healthier choices easier for busy parents and families, today announced new sponsors for the 2016 Building a Healthier Future Summit. The summit will take place May 18 through 20 at the Renaissance Washington D.C. downtown hotel.
NVO: 54.72 (-0.64)
Study Finds Victoza® Significantly Reduced the Risk of Heart Attack and Stroke in People with Type 2 Diabetes
CNW Group - Mon Jun 13, 7:52PM CDT
Diabetes community welcomes news that Victoza(® )reduces the risk of cardiovascular deaths by 22 per cent
NVO: 54.72 (-0.64)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 4:23PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $54.20 to a high of $55.45. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $55.12 on volume of 608,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 54.72 (-0.64)
Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1 diabetes and a comparable HbA(1c) reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
CNW Group - Mon Jun 13, 11:40AM CDT
Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes
NVO: 54.72 (-0.64)
Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
PR Newswire Europe - Mon Jun 06, 6:36AM CDT
BAGSVARD, Denmark, June 6, 2016 /PRNewswire/ --
NVO: 54.72 (-0.64)
Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) - Research and Markets
BusinessWire - Fri Jun 03, 8:34AM CDT
Research and Markets has announced the addition of the "Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
NVO: 54.72 (-0.64)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), NVO: 54.72 (-0.64), SNY: 39.00 (-0.41)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 60.03 (+0.02), NVO: 54.72 (-0.64), BMY: 72.22 (-0.43), SNY: 39.00 (-0.41)
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), NVO: 54.72 (-0.64), SNY: 39.00 (-0.41)
IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
PR Newswire - Tue May 24, 6:39PM CDT
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of Tresiba® (insulin degludec injection 100 Units/mL) and Victoza® (liraglutide) injection for the treatment of adults with type 2 diabetes.
NVO: 54.72 (-0.64)
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Globe Newswire - Tue May 24, 4:24PM CDT
Bagsvaerd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)) for the treatment of adults with type 2 diabetes.
NVO: 54.72 (-0.64)
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 54.72 (-0.64), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), SNY: 39.00 (-0.41)
US and Europe Insulin Market 2016-2020 - Key Vendors are Sanofi, Novo Nordisk & Eli Lilly
GlobeNewswire - Tue May 24, 5:20AM CDT
Research and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering.
NVO: 54.72 (-0.64), LLY: 73.86 (-0.09)
AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 54.72 (-0.64), SCMP: 10.83 (-0.87), SCLN: 14.36 (+0.73), BIOD: 0.33 (-0.01)
Global Non-alcoholic Steatohepatitis Market 2016-2020 - Key Vendors are GSK, Novo Nordisk & Vivus - Research and Markets
BusinessWire - Fri May 20, 11:06AM CDT
Research and Markets has announced the addition of the "Global Non-alcoholic Steatohepatitis Market 2016-2020" report to their offering.
NVO: 54.72 (-0.64)
FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide
Globe Newswire - Fri May 20, 7:36AM CDT
Bagsvaerd, Denmark, 20 May 2016 - Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the 24 May 2016 Advisory Committee meeting to discuss the New Drug Application (NDA) for IDegLira, the fixed combination product of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)).
NVO: 54.72 (-0.64)
Look for Shares of Novo Nordisk to Potentially Rebound after Yesterday's 1.38% Sell Off
Comtex SmarTrend(R) - Thu May 19, 3:26PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $53.45 to a high of $54.12. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $54.01 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 54.72 (-0.64)
Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of haemophilia B
Globe Newswire - Mon May 16, 9:36AM CDT
The paradigm clinical trial programme for nonacog beta pegol enrolled children and adults with severe or moderately severe haemophilia B. A total of 115 previously treated patients with a total of more than 10,625 exposure days for up to 3.3 years of treatment with nonacog beta pegol.
NVO: 54.72 (-0.64)
Novo Nordisk, Chip Ganassi Racing Teams and Charlie Kimball Honor the Diabetes Community With the No. 42 Tresiba® (insulin degludec injection 200 Units/mL) Chevrolet at the 100th Running of the Indianapolis 500
PR Newswire - Mon May 16, 8:30AM CDT
Chip Ganassi Racing Teams (CGRT) and longtime partner Novo Nordisk, a world leader in diabetes care, along with their Verizon IndyCar Series driver Charlie Kimball, will join together to honor the diabetes community at the 100th running of the Indianapolis 500.
NVO: 54.72 (-0.64)
Retail, Food Service, Child Care and Health Care Leaders to Sponsor Partnership for a Healthier America's Building a Healthier Future Summit
PR Newswire - Mon May 09, 5:13PM CDT
The Partnership for a Healthier America (PHA), which works with the private sector and PHA Honorary Chair First Lady Michelle Obama to make healthier choices easier for busy parents and families, today announced new sponsors for the 2016 Building a Healthier Future Summit. The summit will take place May 18 through 20 at the Renaissance Washington D.C. downtown hotel.
NVO: 54.72 (-0.64)
